Sentinel node in melanoma patients: Triple negativity with routine techniques and PCR as positive prognostic factor for survival

Modern Pathology

Volumn 21, Issue 4, 2008, Pages 438-444

  Denninghoff, Valeria C ^a   Falco, Jorge ^b   Kahn, Andrea G ^b   Trouchot, Víctor ^b   Curutchet, Hector P ^b   Elsner, Boris ^b  

^a CEMIC   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Malignant melanoma; Overall survival; PCR; Positive prognostic factor; Sentinel lymph node; Tyrosinase

Indexed keywords

EOSIN; HEMATOXYLIN; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; PROTEIN HMB 45; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 41149145287     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3801020     Document Type: Article

References (28)

1. Milton G, Shaw H, McCarthy W. Occult primary malignant melanoma: factors influencing survival. Br J Surg 1977;64:805-808.
2. Hurt M, Santa Cruz D. Tumour of the skin. In: Fletcher C (ed). Diagnostic Histopathology of Tumours, 2nd edn. Churchill Livingtone: Hong Kong, 2000, pp 1357-1472.
3. Matos E, Loria D, Zangarini N (eds). Atlas de Mortalidad Por Cáncer. Argentina 1997-2001. Loria D: Buenos Aires, 2003.
4. AJCC. Carcinoma of the Skin. In: Lippincott Raven Publishers (eds). AJCC Cancer Staging Manual, 6th edn. Springer Verlag: Philadelphia, 2002, pp 201-220.
5. Elder D, Elenitas R. Lesiones pigmentadas benignas y melanoma maligno. In: Elder D, Elenitas R, Jaworsky C, Johnson B(h) (eds). Lever's Histopatología De La Piel, 8th edn. Editorial Inter Médica: Buenos Aires, 1999, pp 549-594.
6. Milton G, Shaw H, McCarthy W, et al. Prophylactic lymph node dissection in clinical stage l cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982;69:108-111.
7. Reintgen D. Melanoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:105-120.
8. Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
9. Boi S, Cristofolini P, Togni R, et al. Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res 2002;12:147-153.
10. Bostick P, Morton D, Turner R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-3244.
11. Blaheta H, Schittek B, Breuninger H, et al. Detection of melanoma micrometastases in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastases disease in lymph node basin. Am J Surg Pathol 1999;23:822-828.
12. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-1229.
13. Reintgen D, Shivers S. Sentinel lymph node micrometástasis from melanoma. Proven methodology and evolving significance. Cancer 1999;86:551-552.
14. Wang X, Heller R, van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-774.
15. Balch C, Buzaid A, Soong S, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003;21:43-52.
16. Falco J, Mezzadri N, Montesinos M, (eds). Melanoma. Valor Del Mapeo Linfático En La Cirugía Oncológica. Sigma: Buenos Aires, 2002, pp 72-103.
17. Ioachim H, (ed). Metastatic melanoma. Lymph Node Pathology, 2nd edn. JB Lippincott Company: Philadelphia, 1994, pp 674-681.
18. Messina J, Glass L, Cruse C, et al. Pathologic examination of the sentinel lymph node in malignant melanoma. J Am Surg Pathol 1999;23:686-690.
19. Timar J, Csuka O, Orosz Z, et al. Molecular pathology of tumour metastasis. Pathol Oncol Res 2002;8:204-219.
20. Macripo G, Quaglino P, Caliendo V, et al. Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. Melanoma Res 2004;14:S9-S12.
21. Cochran A, Wen D, Morton D. Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 1992;16:214-221.
22. Ross M. The case for elective lymphadenectomy. Surg Oncol Clin N Am 1992;1:205-222.
23. Shivers S, Wang X, Li W, et al. Molecular staging of malignant melanoma. Correlation with clinical outcome. JAMA 1998;280:1410-1415.
24. Cronin C, Ryan A, Talley E, et al. Tyrosine expression during neuroblast divisions affect later pathfinding by retinal ganglion cells. J Neurosci 2003;23:11692-11697.
25. Uribe C, Avila M, Zarate M, et al. Melanoma medular amelanótico. MEDUNAB 2002;5:133-135.
26. Denninghoff V, Kahn A, Falco J, et al. Sentinel lymph node: detection of micrometastases of melanoma. A molecular study. Mol Diagn 2005;8:253-258.
27. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849-2857.
28. Tatlidil C, Parkhill W, Giacomantonio C, et al. Detection of tyrosinase mRNA in the sentinel lymph nodes of melanoma patients is not a predictor short term disease recurrence. Mod Pathol 2007;20:427-434.